Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia

NCT05317403 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05317403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid Leukemia
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2023
Completion date
January 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia refractory, acute myeloid leukemia, in relapse